Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
Healthy Volunteers
NCT05808153

Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2024-05-07

80

Participants Needed

1

Research Sites

149 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Intro Huntington's disease (HD) patients suffer from motor, cognitive and behavioral impairments, with heterogeneous phenotypes and variable time course. This leads to a high variance of HD markers, none of which is currently sensitive enough to 1) measure disease progression from small cohort data, 2) predict disease entry in carriers of the HD mutation (during the prodromal phase or in patients considered asymptomatic: pre-HD patients), and 3) measure a significant evolution of the state of pre-HD patients over a time window compatible with the realization of clinical trials (about 2/3 years). Moreover, the markers of HD do not allow a fine stratification of the patients. Hypothesis/Objective Our objectives are 1) to evaluate the sensitivity of new markers and assessment tools for symptomatic (HD) and presymptomatic (pre-HD) patients, 2) to define a model of disease progression, and 3) to establish an enrichment strategy to improve patient selection for future therapeutic trials. Method We will evaluate newly developed cognitive tests, multimodal imaging techniques, biological markers and use innovative statistical approaches. We will follow 60 patients with the mutation responsible for MH (40 presymptomatic pre-MH patients, 20 symptomatic MH patients) and 20 healthy volunteers (controls) over a 24-month period.

CONDITIONS

Official Title

Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression

Who Can Participate

Age: 18Years - 65Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years to 65 years
  • Written informed consent provided
  • Affiliation with a social security plan or beneficiary rights
  • Healthy controls: UHDRS functional score (TFC) = 13, Motor UHDRS score (TMS) < 6, no known genetic disease or direct relation to HD mutation carriers
  • Manifest carriers: GAC repeats ≥ 40, CAP score ≥ 250, TFC between 10 and 13, TMS > 5 if TFC = 13, diagnostic confidence level = 4, age of disease onset > 20 years, physically able to sign consent
  • Premanifest carriers: GAC repeats ≥ 40, CAP score ≥ 250, TFC = 13, TMS < 6, physically able to sign consent
Not Eligible

You will not qualify if you...

  • Under guardianship or curatorship
  • Neurological or psychiatric disorders unrelated to Huntington's disease
  • Intercurrent illness that may affect performance
  • Chronic progressive neurological disease
  • Claustrophobia
  • Brain injury unrelated to Huntington's disease
  • Presence of pacemaker, intracorporeal metal, intracerebral clips, implantable cardiac devices, metallic intraocular foreign bodies, neurostimulation systems, cochlear or ear implants, drug infusion pumps, chemotherapy pumps, or catheters with metal components
  • Metal fragments such as bullets, pellets, or shrapnel
  • Cerebral artery aneurysm clips, magnetic dental implants, tissue expanders, artificial limbs, hearing aids, or pacemaker piercings
  • Known hypersensitivity to radiopharmaceutical preparations
  • Pregnant or breastfeeding women
  • Persons under state medical aid or deprived of liberty
  • Participation in an interventional study within the last 3 months or in neural transplant/gene therapy trials without time limit
  • Participation in research with radiopharmaceutical injection within the last 12 months
  • Desire to procreate during study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hopital Henri MONDOR

Créteil, Île-de-France Region, France, 94000

Actively Recruiting

Loading map...

Research Team

A

Anne-Catherine BACHOUD-LEVI, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here